SAN FRANCISCO, October 6, 2023 – dQ&A, the leading diabetes research company, today announced that the company will present a total of three abstracts accepted for oral presentation at this year’s European Association for the Study of Diabetes (EASD) Conference, held in Hamburg, Germany October 2-6, 2023. dQ&A’s research and presence at this well-respected conference signifies its ability to provide critical diabetes market research to companies across Europe, the United States, and Canada – to inform product decisions, measure outcomes, and drive better business results. Today, dQ&A works with over 70 industry leaders in insulin, injectables, orals, CGM, BGM, insulin pumps, and AID systems.
“I’m really proud of the research we are presenting at EASD,” said Richard Wood, CEO, dQ&A . “Because we founded dQ&A to make life better for people living with diabetes, having three abstracts accepted for oral presentation at EASD highlights the work of our dedicated and passionate team, the quality of our data and depth of our experience in diabetes.”
Abstracts presented at EASD were:
Trust in sources of diabetes information in six European countries
Mental health coping strategies and glycaemic management among people with diabetes in Europe
Health outcomes and attribute satisfaction for automated insulin delivery systems in six European countries
For more information and to receive a copy of the data presented, send us an email at info@d-qa.com.
__
About dQ&A
For companies seeking to make life better for people with diabetes, dQ&A has been the most trusted data and insights partner since 2009, and the essential source of patient and HCP experience knowledge in the United States, Canada, and Europe. Our unmatched expertise and unique research resources help you tackle challenging business decisions with understanding, empathy, and confidence. dQ&A’s multiple peer-reviewed articles in top medical journals and presentations at scientific meetings are our contribution to making everyone smarter about diabetes, and set us apart as a research leader and innovator truly committed to changing diabetes for the better. Find out more at d-qa.com
